Larvol Delta - LungTimeC02-Effect-of-Infusion-Timing-on-Pathologic-Response-to-Neoadjuvant-Immunotherapy-in-Resectable-NonSmall-Cell-Lung-Cancer

Keytruda (pembrolizumab) - Merck (MSD)

Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology

http://clinicaltrials.gov/ct2/show/NCT07251582

Aug 14, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next